Abstract
CART peptides are endogenous neurotransmitters that are involved in a variety of physiologic functions. Injection of CART 55-102 into the nucleus accumbens produces no effect, but when co-administered with cocaine, it reduces the locomotor and rewarding properties of cocaine. In a human study, subjects carrying a missense mutation of the CART gene exhibited increased anxiety and depression. Also, several animal studies support the idea that CART is involved in anxiety and depression, and they also suggest several possible mechanisms by which this may occur. Thus, there is interesting evidence that CART peptides play a role in anxiety and depression, and that CART peptides may be endogenous antidepressants.
Keywords: CART peptide, antidepressant, depression, forced swim test, anxiety, arousal, drug abuse, CART Peptides, Antidepressants, Psychostimulants, Endogenous, adrenocorticotropin hormone, hypothalamic-pituitary-somatotrophic (HPS) axis
Current Neuropharmacology
Title: CART Peptides Regulate Psychostimulants and May be Endogenous Antidepressants
Volume: 9 Issue: 1
Author(s): M. O. Job, I. M. McNamara and M. J. Kuhar
Affiliation:
Keywords: CART peptide, antidepressant, depression, forced swim test, anxiety, arousal, drug abuse, CART Peptides, Antidepressants, Psychostimulants, Endogenous, adrenocorticotropin hormone, hypothalamic-pituitary-somatotrophic (HPS) axis
Abstract: CART peptides are endogenous neurotransmitters that are involved in a variety of physiologic functions. Injection of CART 55-102 into the nucleus accumbens produces no effect, but when co-administered with cocaine, it reduces the locomotor and rewarding properties of cocaine. In a human study, subjects carrying a missense mutation of the CART gene exhibited increased anxiety and depression. Also, several animal studies support the idea that CART is involved in anxiety and depression, and they also suggest several possible mechanisms by which this may occur. Thus, there is interesting evidence that CART peptides play a role in anxiety and depression, and that CART peptides may be endogenous antidepressants.
Export Options
About this article
Cite this article as:
O. Job M., M. McNamara I. and J. Kuhar M., CART Peptides Regulate Psychostimulants and May be Endogenous Antidepressants, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795017074
DOI https://dx.doi.org/10.2174/157015911795017074 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Differential Mechanisms Underlying Antidepressant Responses of Ketamine and Imipramine
CNS & Neurological Disorders - Drug Targets Ribonucleotide Reductase: A Critical Enzyme for Cancer Chemotherapy and Antiviral Agents
Recent Patents on Anti-Cancer Drug Discovery Metaflammation: Tissue-Specific Alterations of the NLRP3 Inflammasome Platform in Metabolic Syndrome
Current Medicinal Chemistry Preparation, Characterization and in vivo Evaluation of Raloxifene Hydrochloride Solid Lipid Nanoparticles
Pharmaceutical Nanotechnology An Automatic Glioma Segmentation System Using a Multilevel Attention Pyramid Scene Parsing Network
Current Medical Imaging The Use of Antibody Engineering to Create Novel Drugs that Target N-methyl-D-Aspartate Receptors
Current Drug Targets Carbocyclic Analogues of Distamycin and Netropsin
Mini-Reviews in Medicinal Chemistry Effectiveness of Hsp90 Inhibitors as Anti-Cancer Drugs
Mini-Reviews in Medicinal Chemistry Brain-derived Neurotrophic Factor Promotes Growth of Neurons and Neural Stem Cells Possibly by Triggering the Phosphoinositide 3-Kinase/ AKT/Glycogen Synthase Kinase-3β/β-catenin Pathway
CNS & Neurological Disorders - Drug Targets Nutrition as a Health Determinant in Elderly Patients
Current Medicinal Chemistry Novel Therapeutic Approaches to Autoimmune Demyelinating Disorders
Current Pharmaceutical Design Neurobiology and Genetics of Behavioural Syndromes of Alzheimers Disease
Current Alzheimer Research Clinical Assessment of Cognitive Decline in Adults with Down Syndrome
Current Alzheimer Research Novel Detection System for Plant Protein Production of Pharmaceuticals and Impact on Conformational Diseases
Protein & Peptide Letters Neuroprotective Effects of Ellagic Acid in Alzheimer's Disease: Focus on Underlying Molecular Mechanisms of Therapeutic Potential
Current Pharmaceutical Design Anticancer Metallotherapeutics in Preclinical Development
Current Medicinal Chemistry Novel Insights Into the Role of MicroRNA in Lung Cancer Resistance to Treatment and Targeted Therapy
Current Cancer Drug Targets GC-MS Based Metabolic Profiling of Parkinson’s Disease with Glutathione S-transferase M1 and T1 Polymorphism in Tunisian Patients
Combinatorial Chemistry & High Throughput Screening Adverse Drug Reactions and Safety Considerations of NSAIDs: Clinical Analysis
Current Drug Safety Astrocytic 5-HT2B Receptor as in vitro and in vivo Target of SSRIs
Recent Patents on CNS Drug Discovery (Discontinued)